These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10911666)

  • 1. Erythropoietin therapy in peritoneal dialysis patients.
    Morris AT; Ronco C
    Perit Dial Int; 2000; 20 Suppl 2():S178-82. PubMed ID: 10911666
    [No Abstract]   [Full Text] [Related]  

  • 2. [Human recombinant erythropoietin in treatment of uremic anemia in children with continual ambulatory peritoneal dialysis].
    Litwin M; Boguszewska-Baczkowska A; Jelonek A
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):135-6. PubMed ID: 8090665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hematocrit influence on peritoneal dialysis effectiveness during recombinant human erythropoietin treatment in patients with chronic renal failure.
    Ksiazek A; Baranowska-Daca E
    Perit Dial Int; 1993; 13 Suppl 2():S550-2. PubMed ID: 8399662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dialysis dose, membrane type, and anemia control.
    Young EW
    Am J Kidney Dis; 1998 Dec; 32(6 Suppl 4):S157-60. PubMed ID: 9892384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin use in peritoneal dialysis patients.
    Zimmerman SW; Johnson CA
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):38-41. PubMed ID: 1928078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. Ad Hoc Committee for the National Kidney Foundation.
    Am J Kidney Dis; 1989 Sep; 14(3):163-9. PubMed ID: 2672796
    [No Abstract]   [Full Text] [Related]  

  • 7. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness.
    Eschbach JW
    J Am Soc Nephrol; 2002 May; 13(5):1412-4. PubMed ID: 11961032
    [No Abstract]   [Full Text] [Related]  

  • 8. Recombinant human erythropoietin in patients on peritoneal dialysis.
    Bargman J
    Perit Dial Int; 1989; 9(4):245-6. PubMed ID: 2488375
    [No Abstract]   [Full Text] [Related]  

  • 9. Recombinant human erythropoietin: implications for nephrology.
    Eschbach JW; Adamson JW
    Am J Kidney Dis; 1988 Mar; 11(3):203-9. PubMed ID: 3278599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of human recombinant erythropoietin (rHuEPO) for treatment of anemia in patients with chronic kidney failure who don't require additional dialysis therapy].
    Wiecek A
    Przegl Lek; 1995; 52(3):93-4. PubMed ID: 7644683
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of once- versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis.
    Ongkingco JR; Ruley EJ; Turner ME; Fragale MR
    Am J Nephrol; 1994; 14(1):14-8. PubMed ID: 8017476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.
    Sinai-Trieman L; Salusky IB; Fine RN
    J Pediatr; 1989 Apr; 114(4 Pt 1):550-4. PubMed ID: 2926567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematocrit above 30% in continuous ambulatory peritoneal dialysis patients treated with erythropoietin is harmful.
    Junor BJ
    Perit Dial Int; 1993; 13 Suppl 2():S535-7. PubMed ID: 8399658
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythropoietin treatment in peritoneal dialysis patients.
    Nissenson AR
    Perit Dial Int; 1994; 14 Suppl 3():S63-9. PubMed ID: 7948280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of using human recombinant erythropoietin in a patient treated by peritoneal dialysis complicated by chronic infection of the tunnel of the dialysis catheter].
    Wanic-Kossowska M; Grzegorzewska A; Piszczek I; Krzymański M
    Pol Tyg Lek; 1992 Aug 7-17; 47(31-33):694-5. PubMed ID: 1492040
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythropoietic agents in peritoneal dialysis.
    Muirhead N
    Perit Dial Int; 2005; 25(6):547-50. PubMed ID: 16411519
    [No Abstract]   [Full Text] [Related]  

  • 17. [The treatment of renal anemia].
    Koch KM
    Verh Dtsch Ges Inn Med; 1989; 95():246-8. PubMed ID: 2603482
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of blood rheology in the pathogenesis of hypertension of hemodialysis patients treated for renal anemia with recombinant human erythropoietin.
    Baldamus CA; Steffen AM; Brunner R; Pollok M
    Contrib Nephrol; 1990; 82():79-85. PubMed ID: 2093531
    [No Abstract]   [Full Text] [Related]  

  • 19. Erythropoietin 1997: a brief update.
    Gahl GM; Eckardt KU
    Perit Dial Int; 1997; 17 Suppl 2():S84-90. PubMed ID: 9163805
    [No Abstract]   [Full Text] [Related]  

  • 20. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.